CRISPR technology in response to COVID-19 and beyond

Franco Goytia is a serial entrepreneur; currently the CEO of Caspr Biotech, a startup he co-founded at the age of 23. Caspr is using Crispr technology to make better and more accessible molecular diagnostics solutions. Prior to this, at the age of 21, he founded Ando a B2B last-mile logistics solution in LATAM. He did this while studying Economics at Universidad de San Andres in Argentina. Ando was acquired by Moova in 2018. Some of his notable achievements include being selected for the US Dept. State Young Leaders Initiative (YLAI), being an alumni from the Westerwelle Foundation as a Young Founders and having participated of the Indie Bio acceleration program for biotech entrepreneurs in SF. On this episode you'll learn: What is CRISPR and what can it do? [2:20] How has the COVID-19 fallout affected the Buenos Aires startup ecosystem? [14:00] How was CASPR originally using CRISPR to combate the Zika Virus?[18:15]